Edenbridge Pharmaceuticals, LLC

Edenbridge Pharmaceuticals focuses on developing and distributing pharmaceutical products, primarily bumetanide, a loop diuretic essential for managing heart failure and hypertension. Founded in 2008 and headquartered in Parsippany-Troy Hills, US, Edenbridge Pharmaceuticals operates as Dexcel Pharma USA, specializing in pharmaceutical product development. CEO Douglas Boothe, alongside Ryan Collins, leads the company, which has successfully completed two funding deals, the most recent on January 31, 2017. Edenbridge Pharmaceuticals, now operating as Dexcel Pharma USA, specializes in the development and distribution of pharmaceutical products, focusing on bumetanide, a potent loop diuretic.

Bumetanide is utilized to manage conditions such as heart failure, edema, and hypertension, requiring precise dose selection and consistent patient monitoring due to its high potency. The company leverages the Belgian reference portal localpharma. be to provide real-time data on bumetanide formulations, including brand and generic options, approved strengths, bioequivalence findings, and supply status. This service is designed to enhance the prescribing process for healthcare professionals, ensuring they have access to critical information regarding medication safety, pricing, and reimbursement status.

Dexcel Pharma USA primarily markets its products to healthcare providers and institutions across the United States, aiming to improve patient outcomes through effective medication management. Dexcel Pharma USA generates revenue through the sale of its pharmaceutical products, particularly bumetanide. Transactions typically occur through partnerships with healthcare providers, hospitals, and pharmacies, facilitating a structured supply chain that supports both direct-to-consumer and B2B sales. The pricing structure for bumetanide and related products accommodates various reimbursement models, allowing prescribers to consider patient copayment options.

This pricing strategy is integral to ensuring accessibility for patients while reinforcing the value proposition of Dexcel Pharma USA’s offerings. Revenue is significantly influenced by the volume of prescriptions written and the ongoing relationships established with healthcare providers, ensuring a steady flow of transactions in the market. Edenbridge Pharmaceuticals aims to expand its product line and develop new formulations of bumetanide. Additionally, the company is exploring entry into new geographic markets, particularly in Europe and Asia, with plans to initiate this expansion by 2025.

Recent funding will be allocated to support research and development initiatives, enhance distribution capabilities, and facilitate market entry strategies.